Clinical Trial Update: An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety of four doses of autologous muscle-derived cells for stress urinary incontinence; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stress Urinary Incontinence

Drugs mentioned

• Autologous Muscle Derived Cells (autologous muscle-derived cells)

Snippet

Sponsor: Cook MyoSite | Conditions: Stress Urinary Incontinence, Cell Therapy | Phase 2 | Status: COMPLETED | Results posted: 2014-01-01